Nishimura, M., Toyoda, M., Takenaka, K., Imamura, Y., Chayahara, N., Kiyota, N., . . . Minami, H. (2016). The combination of HLA-B*15: 01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol.
Citação norma ChicagoNishimura, Meiko, et al. "The Combination of HLA-B*15: 01 and DRB1*15:01 Is Associated With Gemcitabine Plus Erlotinib-induced Interstitial Lung Disease in Patients With Advanced Pancreatic Cancer." Cancer Chemother Pharmacol 2016.
Citação norma MLANishimura, Meiko, et al. "The Combination of HLA-B*15: 01 and DRB1*15:01 Is Associated With Gemcitabine Plus Erlotinib-induced Interstitial Lung Disease in Patients With Advanced Pancreatic Cancer." Cancer Chemother Pharmacol 2016.